DÜSSELDORF, Germany: LenioBio GmbH, a TechBio company commercializing its ALiCE® cell-free protein expression platform, today announced a collaborative agreement with Twist Bioscience Corporation. The collaboration will integrate our ALiCE® platform with Twist’s DNA manufacturing and automation capabilities to accelerate the design–build–test cycle for protein expression services-delivering experimental results back to customers’ and partners’ AI models faster.

“AI can design new protein molecules for biologic drugs: the problem is that reality doesn’t always reflect what the computer imagines,” said André Goerke, CEO of LenioBio. “Bringing together Twist’s highly automated manufacturing and characterization capabilities with LenioBio’s ALiCE® system for cell-free protein expression, can enable rapid data generation from real-world molecules. The resulting data can then be fed back into the AI model as a tight lab-in-the-loop iteration-so design decisions are driven by fresh experimental evidence, without waiting weeks for expression bottlenecks.”

Why this matters: In AI-driven protein and antibody design, advantage comes from iteration speed and the quality of biology-native data. This collaboration will help teams run faster, higher-throughput lab-in-the-loop cycles with rapid, eukaryotic cell-free expression.

The ALiCE® platform enables production of full-length, folded, functional proteins within 24 hours-compressing timelines versus traditional cell-based systems and reducing the latency between computational design and wet-lab validation. Compared to other cell-free systems, ALiCE® supports complex molecules with eukaryotic characteristics that are difficult to produce in alternative platforms. By implementing ALiCE®, Twist will expand and complement its existing protein expression capabilities.

“AI-led antibody development is one of the most exciting growth areas in biologics where speed of iteration and quality of experimental readouts directly shape model performance and decision-making,” said Emily M. Leproust, CEO and co-founder of Twist Bioscience. “To enable our customers working in AI-enabled drug discovery, we built out our characterization offering and now we’re continuing to expand it. Through this collaboration with LenioBio, we will be able to add cell-free protein expression to our offering.”

Fonte: Business Wire